ATE411043T1 - Verfahren von dna-impfung - Google Patents

Verfahren von dna-impfung

Info

Publication number: ATE411043T1
Authority: AT; Austria
Prior art keywords: compound; mammal; procedure; disease state; antigenic peptide
Prior art date: 1998-08-26

Application number

AT99944505T

Other languages

English (en)

Inventor

Jehad Charo

Rolf Kiessling

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-26

Filing date

1999-08-25

Publication date

2008-10-15

1999-08-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE411043T1 publication Critical patent/ATE411043T1/de

Links

238000000034 method Methods 0.000 title abstract 2
238000011238 DNA vaccination Methods 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
230000000890 antigenic effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 abstract 1
230000024932 T cell mediated immunity Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
230000028996 humoral immune response Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229950009795 tucaresol Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99944505T 1998-08-26 1999-08-25 Verfahren von dna-impfung ATE411043T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9818627.3A GB9818627D0 (en)	1998-08-26	1998-08-26	Improvements in dva vaccination

Publications (1)

Publication Number	Publication Date
ATE411043T1 true ATE411043T1 (de)	2008-10-15

Family

ID=10837881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99944505T ATE411043T1 (de)	1998-08-26	1999-08-25	Verfahren von dna-impfung

Country Status (22)

Country	Link
US (1)	US7074770B1 (de)
EP (1)	EP1107785B1 (de)
JP (1)	JP2002523469A (de)
KR (1)	KR20010072983A (de)
CN (1)	CN1326358A (de)
AT (1)	ATE411043T1 (de)
AU (1)	AU747643B2 (de)
BR (1)	BR9913323A (de)
CA (1)	CA2341544A1 (de)
CZ (1)	CZ2001717A3 (de)
DE (1)	DE69939747D1 (de)
ES (1)	ES2313791T3 (de)
GB (1)	GB9818627D0 (de)
HU (1)	HUP0103214A3 (de)
IL (1)	IL141623A0 (de)
NO (1)	NO20010922L (de)
NZ (1)	NZ510206A (de)
OA (1)	OA11644A (de)
PL (1)	PL346299A1 (de)
TR (1)	TR200101256T2 (de)
WO (1)	WO2000012121A1 (de)
ZA (1)	ZA200101539B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7223739B1 (en)	1995-06-07	2007-05-29	Powderject Vaccines, Inc.	Adjuvanted genetic vaccines
US7022320B1 (en)	1999-02-09	2006-04-04	Powderject Vaccines, Inc.	Mycobacterium tuberculosis immunization
GB9923309D0 (en) *	1999-10-01	1999-12-08	Glaxo Group Ltd	Assay
ATE460945T1 (de) *	1999-11-03	2010-04-15	Powderject Vaccines Inc	Genetische adjuvanz-impfstoffe
DK1227840T3 (da) *	1999-11-03	2008-02-04	Powderject Vaccines Inc	Adjuverede, genetiske vacciner
WO2001076626A2 (en) *	2000-04-11	2001-10-18	Galenica Pharmaceuticals, Inc.	Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
GB0023008D0 (en) *	2000-09-20	2000-11-01	Glaxo Group Ltd	Improvements in vaccination
AU2004251949B2 (en) *	2003-06-27	2009-05-07	Kyowa Hakko Kirin Co., Ltd.	Hsp90 family protein inhibitors
CN100415876C (zh) *	2003-09-05	2008-09-03	杭州浙大康泰生物技术有限公司	艾滋病重组腺病毒疫苗
CA2784488A1 (en)	2009-12-16	2011-06-23	Chrontech Pharma Ab	Injection needle and device
KR20140068000A (ko)	2011-06-15	2014-06-05	크론테크 파마 아베	주사 바늘 및 장치
PL2797416T3 (pl)	2011-12-28	2017-12-29	Global Blood Therapeutics, Inc.	Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
US9012450B2 (en)	2011-12-28	2015-04-21	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014064534A2 (en)	2012-10-05	2014-05-01	Chrontech Pharma Ab	Injection needle, device, immunogenic compositions and method of use
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (de)	2013-03-15	2021-01-20	Global Blood Therapeutics, Inc.	Verbindungen und verwendungen davon zur modulation von hämoglobin
JP6426694B2 (ja)	2013-03-15	2018-11-21	グローバルブラッドセラピューティクスインコーポレイテッド	ヘモグロビンの修飾のための化合物及びその使用
WO2014145040A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt)	2013-03-15	2022-12-13	Global Blood Therapeutics, Inc	Compostos e seus usos para a modulação de hemoglobina
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
AP2016009261A0 (en)	2014-02-07	2016-06-30	Global Blood Therapeutics Inc	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3110448B1 (de) *	2014-02-26	2020-09-09	The Board of Regents of The University of Texas System	Nitrobenzaldehydprotonfreisetzung zur manipulation von zellulärer azidose
HK1249052A1 (zh)	2015-03-06	2018-10-26	BeyondSpring Pharmaceuticals Inc.	治疗与ras突变相关的癌症的方法
US11267807B2 (en) *	2015-10-28	2022-03-08	The Brigham And Women's Hospital, Inc.	Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy
PL3383392T3 (pl)	2015-12-04	2025-11-17	Global Blood Therapeutics, Inc.	Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
US10912748B2 (en)	2016-02-08	2021-02-09	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
TWI663160B (zh)	2016-05-12	2019-06-21	全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
CN109475524A (zh)	2016-06-06	2019-03-15	万春药业公司	用于减少中性粒细胞减少症的组合物和方法
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018129381A1 (en)	2017-01-06	2018-07-12	Beyondspring Pharmaceuticals, Inc.	Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko)	2017-02-01	2019-09-25	비욘드스프링 파마수티컬스, 인코포레이티드.	호중구감소증의 감소 방법
WO2019147615A1 (en)	2018-01-24	2019-08-01	Beyondspring Pharmaceuticals, Inc.	Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232238B (zh) *	2018-08-29	2022-05-17	北京勤邦生物技术有限公司	吉非罗齐半抗原、人工抗原和抗体及其制备方法和用途
EP3860975B1 (de)	2018-10-01	2023-10-18	Global Blood Therapeutics, Inc.	Modulatoren von hämoglobin zur behandlung von sichelzellenanämie
CN112778155B (zh) *	2019-11-11	2023-08-11	大连万春布林医药有限公司	妥卡雷琐衍生物及其用途
US20230355557A1 (en) *	2020-08-26	2023-11-09	Gertrude Biomedical Pty Ltd	Antiviral sox inhibitors
EP4319751A4 (de)	2021-04-09	2025-02-26	Beyondspring Pharmaceuticals, Inc.	Therapeutische zusammensetzungen und verfahren zur behandlung von tumoren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5620896A (en) *	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
EP0609606B1 (de)	1992-10-01	1996-12-11	The Wellcome Foundation Limited	Tucaresol als Mittel zur Immunopotentierung
TW404844B (en) *	1993-04-08	2000-09-11	Oxford Biosciences Ltd	Needleless syringe
ATE475668T1 (de)	1994-01-27	2010-08-15	Univ Massachusetts Medical	Immunisierung durch impfung von dns transkriptionseinheit

1998
- 1998-08-26 GB GBGB9818627.3A patent/GB9818627D0/en not_active Ceased
1999
- 1999-08-25 JP JP2000567235A patent/JP2002523469A/ja active Pending
- 1999-08-25 EP EP99944505A patent/EP1107785B1/de not_active Expired - Lifetime
- 1999-08-25 ES ES99944505T patent/ES2313791T3/es not_active Expired - Lifetime
- 1999-08-25 CZ CZ2001717A patent/CZ2001717A3/cs unknown
- 1999-08-25 WO PCT/EP1999/006217 patent/WO2000012121A1/en not_active Ceased
- 1999-08-25 NZ NZ510206A patent/NZ510206A/en unknown
- 1999-08-25 HU HU0103214A patent/HUP0103214A3/hu unknown
- 1999-08-25 AU AU57402/99A patent/AU747643B2/en not_active Ceased
- 1999-08-25 PL PL99346299A patent/PL346299A1/xx not_active Application Discontinuation
- 1999-08-25 BR BR9913323-7A patent/BR9913323A/pt not_active IP Right Cessation
- 1999-08-25 KR KR1020017002431A patent/KR20010072983A/ko not_active Withdrawn
- 1999-08-25 CA CA002341544A patent/CA2341544A1/en not_active Abandoned
- 1999-08-25 IL IL14162399A patent/IL141623A0/xx unknown
- 1999-08-25 DE DE69939747T patent/DE69939747D1/de not_active Expired - Lifetime
- 1999-08-25 OA OA1200100050A patent/OA11644A/en unknown
- 1999-08-25 AT AT99944505T patent/ATE411043T1/de not_active IP Right Cessation
- 1999-08-25 US US09/763,462 patent/US7074770B1/en not_active Expired - Fee Related
- 1999-08-25 TR TR2001/01256T patent/TR200101256T2/xx unknown
- 1999-08-25 CN CN99812463A patent/CN1326358A/zh active Pending
2001
- 2001-02-23 NO NO20010922A patent/NO20010922L/no not_active Application Discontinuation
- 2001-02-23 ZA ZA200101539A patent/ZA200101539B/en unknown

Also Published As

Publication number	Publication date
CA2341544A1 (en)	2000-03-09
US7074770B1 (en)	2006-07-11
PL346299A1 (en)	2002-01-28
ES2313791T3 (es)	2009-03-01
JP2002523469A (ja)	2002-07-30
AU5740299A (en)	2000-03-21
AU747643B2 (en)	2002-05-16
OA11644A (en)	2004-11-22
KR20010072983A (ko)	2001-07-31
TR200101256T2 (tr)	2001-10-22
HUP0103214A2 (hu)	2001-12-28
BR9913323A (pt)	2001-12-04
WO2000012121A1 (en)	2000-03-09
ZA200101539B (en)	2002-02-25
EP1107785A1 (de)	2001-06-20
NO20010922D0 (no)	2001-02-23
CZ2001717A3 (cs)	2001-10-17
IL141623A0 (en)	2002-03-10
NZ510206A (en)	2003-08-29
EP1107785B1 (de)	2008-10-15
NO20010922L (no)	2001-04-23
DE69939747D1 (de)	2008-11-27
CN1326358A (zh)	2001-12-12
GB9818627D0 (en)	1998-10-21
HUP0103214A3 (en)	2003-10-28

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69939747D1 (de)	2008-11-27	Verfahren von dna-impfung
DE60228758D1 (de)	2008-10-16	Immunisierung gegen chlamydia tracheomatis
BR9608615A (pt)	1999-06-15	Vacinas de vírus sincicial respiratório de ácido nucléico
EP0773295A3 (de)	1999-06-16	Auf DNA beruhende Impfung von Fischen durch Wässerung
PT912898E (pt)	2002-05-31	Metodo imunologico de deteccao de anticorpos dirigidos contra a transglutaminase (ttg) utilizacao de ttg para o diagnostico e controlo de terapia assim como agente farmaceutico oral contendo ttg
EP1568373A3 (de)	2005-12-21	Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen
DE60139690D1 (de)	2009-10-08	Immunisierung gegen chlamydia pneumoniae
AU7814498A (en)	1998-12-30	Multivalent (in ovo) avian vaccine
DE69918146D1 (de)	2004-07-22	Verfahren zur therapeutischen impfung
ATE262348T1 (de)	2004-04-15	Mittel zur verabreichung von antigenen
EP1964573A3 (de)	2011-03-02	Verfahren zur Induzierung und/oder Verbesserung einer Immunreaktion auf Tumorantigene
UA41381C2 (uk)	2001-09-17	Спосіб вакцинації птиці in ovo проти кокцидіозу
ECSP024257A (es)	2002-08-01	Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
EP1932915A3 (de)	2009-04-01	Materialien und Verfahren im Zusammenhang mit verbesserten Impfstrategien
DE69635472D1 (de)	2005-12-29	Impfstoff gegen Geflügelkokzidose
DE69521007D1 (de)	2001-06-28	Impfstoff gegen Geflügelkokzidose
EA200301125A1 (ru)	2004-04-29	Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
RU2003110420A (ru)	2005-01-10	Дифференцирование gnrh-i и gnrh-ii
EP0839913A3 (de)	1999-06-16	Auf DNA beruhende Impfung von Fishen durch Wässerung
SE8803062D0 (sv)	1988-09-01	Sequential polypeptides endowed with immunological activity
DE60021523D1 (de)	2005-09-01	Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren
EP1502602A3 (de)	2006-05-17	Verfahren zur therapeutischen Impfung
NO20005321L (no)	2000-12-20	Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
RU97101181A (ru)	1999-02-27	Полинуклеотидная вакцина для вируса папилломы
Kanfer	1990	Pigs always get slaughtered.